ClinicalTrials.gg
TerminatedNCT04716725Updated May 15, 2026Results posted

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

A Phase 2 interventional study of 68Ga-PSMA-11 and Positron Emission Tomography (PET) in Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma and Stage IV Prostate Cancer AJCC v8, sponsored by Thomas Hope. Terminated at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Thomas Hope · Phase 2, Interventional, and Diagnostic

How we know

Why this study was terminated
Low accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms — 8 open to participants now, 11 under way, 3 of them phase 3. gallium 68 PSMA-11 · Prostatic Neoplasms.

Enrollment
35th of 49
15 · median 50
Started
2021
with 5 others
Phase 2
19 of 49
1 open now
Registered
32nd of 49
by date
Lead sponsor
4 of 49
Thomas Hope

Among the 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms, this one is the 35th largest by enrollment, is one of 6 that started in 2021, is one of 19 in phase 2, and was the 32nd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About gallium 68 PSMA-11

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This phase II trial studies the use of 68Ga-PSMA-11 positron emission tomography (PET) in diagnosing patients with prostate cancer that continues to grow despite the surgical removal of the testes or medical intervention to block androgen production (castration resistant), and has spread to other places in the body (metastatic). 68Ga- PSMA-11 is a new imaging agent that may help get more detailed pictures of the tumor. This trial aims to see whether using 68Ga-PSMA-11 PET scans may help doctors learn more about where disease is located in the body.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine whether the percent change from baseline to 16 weeks (+/- 8 weeks) in maximum standard uptake value (SUVmax) averaged across up to 16 lesions per patient (SUVmax-ave) is associated with >= 50% decline from baseline in serum prostate specific antigen (PSA50) response.

SECONDARY OBJECTIVES:

I. To determine whether the percent change from baseline in SUVmax-ave on PSMA PET is associated with time-to-event endpoints including PSA progression-free survival and overall survival.

II. To determine whether the percent change from baseline in SUVmax on PSMA PET is associated with objective response by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 on a per-lesion basis among measurable soft tissue lesions present at baseline.

EXPLORATORY (CORRELATIVE) OBJECTIVES:

I. To descriptively characterize the histologic, transcriptional, and genomic features of PSMA low/negative lesions among patients who undergo paired optional metastatic tumor biopsy.

II. To descriptively characterize the relationship between SUVmax-ave on baseline Ga-PSMA PET with optional baseline fludeoxyglucose F-18 (FDG)-PET.

III. To determine whether heterogeneity of PSMA expression on baseline Ga-PSMA PET is associated with overall survival.

IV. To descriptively characterize the patterns of PSMA expression at the time of disease progression among patients who undergo optional PSMA PET.

V. To determine whether the percent change from baseline in PSMA PET is associated with PSA50 response among subgroups of patients defined by treatment modality received, including androgen receptor (AR) targeting treatment, PSMA-targeting radioligand therapy, cytotoxic chemotherapy, and immunotherapy.

OUTLINE:

Patients receive gallium Ga 68-PSMA-11 intravenously (IV) and undergo PET at baseline, 16 weeks after initiating therapy, and at time of disease progression.

After progression or study completion, patients are followed up every 3 months for up to 24 months

03

Conditions studied

  • Castration-Resistant Prostate Carcinoma
  • Metastatic Prostate Carcinoma
  • Stage IV Prostate Cancer AJCC v8
  • Stage IVA Prostate Cancer AJCC v8
  • Stage IVB Prostate Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sub-cohort A1: Patients must have baseline evaluations performed within 12 weeks prior to the start of systemic therapy.
  2. Sub-cohort A2: Patients must meet all the following requirements:

    • Have had a baseline pre-treatment 68Ga-PSMA-11 PET scan and PSA measurement performed within 12 weeks prior to the start of current systemic therapy.
    • Able to have an on-treatment 68Ga-PSMA-11 PET and a PSA measurement within 16 weeks (+/- 8 weeks) after the start of current systemic therapy.

    Note: The screening period for sub-cohort A2 is within 24 weeks after the patient started their current systemic therapy.

  3. Patients must have progressive castration resistant prostate cancer, according to PCWG3 criteria.
  4. Patients must have planned initiation of systemic treatment (sub-cohort A1), or ongoing systemic treatment (sub-cohort A2) for castration resistant prostate cancer within 12 weeks of baseline Ga-PSMA PET.
  5. Patients must have at least one lesion with PSMA uptake at or above the blood pool on their baseline PSMA PET scan.
  6. The patient must be able and willing to comply with study procedures and provide signed and dated .
  7. (ECOG) performance status of 0 or 1.
  8. Patient must be Aged 18 years or older at the time of study entry.
  9. Patients who undergo optional metastatic tumor following completion of baseline Ga-PSMA PET must additionally meet all of the following criteria:

    • Presence of one or more metastases by standard radiographic scans that is safely accessible to tumor biopsy in the judgment of treating clinician and/or Interventional Radiology.
    • No history of radiation therapy to the target metastatic lesion selected for tumor biopsy.
    • No to biopsy including uncontrolled bleeding diathesis.
    • > 75,000/ul and (PT) or institution normalized ratio (INR) and a partial thromboplastin time (PTT) \< 1.5 times the institutional (ULN) within 14 days prior to biopsy.

Exclusion criteria

Exclusion Criteria:

  1. Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid .
  2. Patients with any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.
  3. Patients with any to magnetic resonance imaging (MRI) (e.g. pacemaker placement, severe claustrophobia) Note: The exclusion criteria above (3) is only applicable for patients scheduled for a Positron Emission Tomography (PET) MRI (PET/MRI).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Experimental (68Ga-PSMA-11 PET)

    Patients receive gallium 68Ga-PSMA-11 IV and undergo PET at baseline, 16 weeks after initiating therapy, and at time of disease progression.

    Drug: 68Ga-PSMA-11 · Procedure: Positron Emission Tomography (PET)

Interventions

  • DrugGallium 68 PSMA-11Studies of Gallium 68 PSMA-11Gallium 68 PSMA-11 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: 68Ga Prostate-specific Membrane Antigen (PSMA) 11, Gallium Ga-68 gozetotide, Gallium-68 PSMA, Gallium Ga 68 PSMA-11, Gallium Ga 68-labeled PSMA-11

  • ProcedurePositron Emission Tomography (PET)

    Undergo PET

    Also known as: PET, PET Scan

06

What researchers measure

Primary outcomes

  1. Mean Maximum Standard Uptake Value (SUVmax)

    The mean SUVmax and standard deviation across the primary tumor and the 5 largest lesions in each of three metastatic sites (nodal, visceral and osseous; for a maximum of 16 lesions per patient) will be descriptively reported.

    Time frame: Baseline, and up to 16 weeks after initiation of therapy

  2. Median SUVmax

    The median and range of SUVmax across the primary tumor and the 5 largest lesions in each of three metastatic sites (nodal, visceral and osseous; for a maximum of 16 lesions per patient) will be descriptively reported.

    Time frame: Baseline, and up to 16 weeks after initiation of therapy

  3. Percentage of Participants Who Progressed by Prostate-specific Antigen (PSA) Response Group

    The percent of participants who fall into the PSA50 responders vs. non-responders based on PSMA treatment response criteria (PPP) for progression status will be reported. PPP uses 3 different criteria to determine response: 1) Appearance of 2 or more new PSMA positive distant lesions, 2) Appearance of 1 new PSMA positive lesion plus consistent clinical and/or laboratory data and recommended confirmation by biopsy or correlative imaging within 3 months of PSMA PET, and 3) Increase in size or PSMA uptake of 1 or more existing lesions by 30% plus consistent clinical and/or laboratory data and/or confirmation by biopsy or correlative imaging within 3 months of PSMA PET.

    Time frame: Baseline, and up to 16 weeks after initiation of therapy

Secondary outcomes

  1. Progression Free Survival (PFS) by PET Response Group

    The study cohort will be dichotomized by participants who fall into the responders vs. non-responders (progressed vs not progressed) based on PSMA PET response criteria (PPP) for progression status will be reported. PPP uses 3 different criteria to determine response: 1) Appearance of 2 or more new PSMA positive distant lesions, 2) Appearance of 1 new PSMA positive lesion plus consistent clinical and/or laboratory data and recommended confirmation by biopsy or correlative imaging within 3 months of PSMA PET, and 3) Increase in size or PSMA uptake of 1 or more existing lesions by 30% plus consistent clinical and/or laboratory data and/or confirmation by biopsy or correlative imaging within 3 months of PSMA PET. PSA progression-free will be defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3). The median PFS in months with 95% confidence interval will be reported.

    Time frame: Up to 48 months

  2. Objective Response by PET Response Group

    The study cohort will be dichotomized by participants who fall into the responders vs. non-responders (progressed vs not progressed) based on PSMA PET response criteria (PPP) for progression status will be reported. PPP uses 3 different criteria to determine response: 1) Appearance of 2 or more new PSMA positive distant lesions, 2) Appearance of 1 new PSMA positive lesion plus consistent clinical and/or laboratory data and recommended confirmation by biopsy or correlative imaging within 3 months of PSMA PET, and 3) Increase in size or PSMA uptake of 1 or more existing lesions by 30% plus consistent clinical and/or laboratory data and/or confirmation by biopsy or correlative imaging within 3 months of PSMA PET. PSA progression-free will be defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3). The percentage of participants who obtained an objective response per Response Evaluation Criteria in Solid Tumors (RECIST) will be reported.

    Time frame: Baseline, and up to 16 weeks after initiation of therapy

  3. Overall Survival (OS) by PET Response Group

    The study cohort will be dichotomized by participants who fall into the responders vs. non-responders (progressed vs not progressed) based on PSMA PET response criteria (PPP) for progression status will be reported. PPP uses 3 different criteria to determine response: 1) Appearance of 2 or more new PSMA positive distant lesions, 2) Appearance of 1 new PSMA positive lesion plus consistent clinical and/or laboratory data and recommended confirmation by biopsy or correlative imaging within 3 months of PSMA PET, and 3) Increase in size or PSMA uptake of 1 or more existing lesions by 30% plus consistent clinical and/or laboratory data and/or confirmation by biopsy or correlative imaging within 3 months of PSMA PET. PSA progression-free will be defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3). The median OS and 95% confidence interval will be reported.

    Time frame: Up to 48 months

07

Results

Posted Oct 16, 2024
Limitations and caveats
Participant enrollment closed earlier than anticipated due to slow accrual

Participant flow

Participant flow — Overall Study
MilestoneExperimental (68Ga-PSMA-11 PET)
Started15
Completed15
Not completed0

Outcome measures

PrimaryMean Maximum Standard Uptake Value (SUVmax)

The mean SUVmax and standard deviation across the primary tumor and the 5 largest lesions in each of three metastatic sites (nodal, visceral and osseous; for a maximum of 16 lesions per patient) will be descriptively reported.

Time frame:
Baseline, and up to 16 weeks after initiation of therapy

No measurements were reported for this outcome.

PrimaryMedian SUVmax

The median and range of SUVmax across the primary tumor and the 5 largest lesions in each of three metastatic sites (nodal, visceral and osseous; for a maximum of 16 lesions per patient) will be descriptively reported.

Time frame:
Baseline, and up to 16 weeks after initiation of therapy

No measurements were reported for this outcome.

PrimaryPercentage of Participants Who Progressed by Prostate-specific Antigen (PSA) Response Group

The percent of participants who fall into the PSA50 responders vs. non-responders based on PSMA treatment response criteria (PPP) for progression status will be reported. PPP uses 3 different criteria to determine response: 1) Appearance of 2 or more new PSMA positive distant lesions, 2) Appearance of 1 new PSMA positive lesion plus consistent clinical and/or laboratory data and recommended confirmation by biopsy or correlative imaging within 3 months of PSMA PET, and 3) Increase in size or PSMA uptake of 1 or more existing lesions by 30% plus consistent clinical and/or laboratory data and/or confirmation by biopsy or correlative imaging within 3 months of PSMA PET.

Time frame:
Baseline, and up to 16 weeks after initiation of therapy
Reported as:
Number · percentage of participants by group
Percentage of Participants Who Progressed by Prostate-specific Antigen (PSA) Response Group
percentage of participants by groupExperimental (68Ga-PSMA-11 PET)
PSA Responders who progressed11.1
PSA Non-Responders who progressed83.3
SecondaryProgression Free Survival (PFS) by PET Response Group

The study cohort will be dichotomized by participants who fall into the responders vs. non-responders (progressed vs not progressed) based on PSMA PET response criteria (PPP) for progression status will be reported. PPP uses 3 different criteria to determine response: 1) Appearance of 2 or more new PSMA positive distant lesions, 2) Appearance of 1 new PSMA positive lesion plus consistent clinical and/or laboratory data and recommended confirmation by biopsy or correlative imaging within 3 months of PSMA PET, and 3) Increase in size or PSMA uptake of 1 or more existing lesions by 30% plus consistent clinical and/or laboratory data and/or confirmation by biopsy or correlative imaging within 3 months of PSMA PET. PSA progression-free will be defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3). The median PFS in months with 95% confidence interval will be reported.

Time frame:
Up to 48 months
Reported as:
Median · months
Progression Free Survival (PFS) by PET Response Group
monthsExperimental (68Ga-PSMA-11 PET)
Not Progressed37.5 (12.7 to NA)
Progressed5.4 (4.4 to 15.2)
SecondaryObjective Response by PET Response Group

The study cohort will be dichotomized by participants who fall into the responders vs. non-responders (progressed vs not progressed) based on PSMA PET response criteria (PPP) for progression status will be reported. PPP uses 3 different criteria to determine response: 1) Appearance of 2 or more new PSMA positive distant lesions, 2) Appearance of 1 new PSMA positive lesion plus consistent clinical and/or laboratory data and recommended confirmation by biopsy or correlative imaging within 3 months of PSMA PET, and 3) Increase in size or PSMA uptake of 1 or more existing lesions by 30% plus consistent clinical and/or laboratory data and/or confirmation by biopsy or correlative imaging within 3 months of PSMA PET. PSA progression-free will be defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3). The percentage of participants who obtained an objective response per Response Evaluation Criteria in Solid Tumors (RECIST) will be reported.

Time frame:
Baseline, and up to 16 weeks after initiation of therapy
Reported as:
Number · percentage of participants
Objective Response by PET Response Group
percentage of participantsExperimental (68Ga-PSMA-11 PET)
Not Progressed33
Progressed0
SecondaryOverall Survival (OS) by PET Response Group

The study cohort will be dichotomized by participants who fall into the responders vs. non-responders (progressed vs not progressed) based on PSMA PET response criteria (PPP) for progression status will be reported. PPP uses 3 different criteria to determine response: 1) Appearance of 2 or more new PSMA positive distant lesions, 2) Appearance of 1 new PSMA positive lesion plus consistent clinical and/or laboratory data and recommended confirmation by biopsy or correlative imaging within 3 months of PSMA PET, and 3) Increase in size or PSMA uptake of 1 or more existing lesions by 30% plus consistent clinical and/or laboratory data and/or confirmation by biopsy or correlative imaging within 3 months of PSMA PET. PSA progression-free will be defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3). The median OS and 95% confidence interval will be reported.

Time frame:
Up to 48 months
Reported as:
Median · months
Overall Survival (OS) by PET Response Group
monthsExperimental (68Ga-PSMA-11 PET)
Not ProgressedNA (NA to NA)
Progressed33.3 (17.6 to 36.6)

Adverse events

Collected over Up to 2 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental (68Ga-PSMA-11 PET)3/15 (20%)0/15 (0%)0/15 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Participants)Experimental (68Ga-PSMA-11 PET)
40-49 years old1
50-59 years old2
60-69 years old2
70-79 years old8
80-89 years old2
Sex: Female, Male
Sex: Female, Male(Participants)Experimental (68Ga-PSMA-11 PET)
Female0
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental (68Ga-PSMA-11 PET)
Hispanic or Latino0
Not Hispanic or Latino15
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental (68Ga-PSMA-11 PET)
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American0
White12
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Experimental (68Ga-PSMA-11 PET)
United States15
08

Study locations

1 site
  • University of California San Francisco
    San Francisco, California 94143, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Sep 2023, 24 months.

Results were first posted in Oct 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2021
First posted
Jan 20, 2021
StartActual
Sep 28, 2021
Primary completionActual
Sep 30, 2023
CompletionActual
Apr 30, 2025
Results first posted
Oct 16, 2024
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04716725
Lead sponsor
Thomas Hope
Collaborators
Conquer Cancer Foundation, Gateway for Cancer Research, Prostate Cancer Foundation
Responsible party
Thomas Hope (Co-Principal Investigator (IND Holder), University of California, San Francisco) — Sponsor-investigator
First posted
Jan 20, 2021
Start date
Sep 28, 2021
Primary completion
Sep 30, 2023
Completion
Apr 30, 2025
Results posted
Oct 16, 2024
Last update
May 15, 2026

Study contacts

Ivan A de Kouchovsky, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium 68 PSMA-11

Start the discussion